Human pregnane X receptor: A novel target for anticancer drug development

Drug Discovery Today

Volumn 19, Issue 1, 2014, Pages 63-70

  Rathod, Vijay ^a   Jain, Sumit ^a   Nandekar, Prajwal ^a   Sangamwar, Abhay T ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR;

CLINICAL EVALUATION; COMPUTER MODEL; DRUG BINDING; DRUG DETERMINATION; DRUG TARGETING; EXPERIMENTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONKEY MODEL; MOUSE MODEL; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; TRANSACTIVATION ASSAY; ZEBRA FISH;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, STEROID;

EID: 84891879382     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.08.009     Document Type: Review

References (72)

1. J.A. DiMasi, and H.G. Grabowski Economics of new oncology drug development J. Clin. Oncol. 25 2007 209 216
2. M.W. Sinz Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development Drug Metab. Rev. 45 2013 3 14
3. S. Ich Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals 2008 November
4. S. Marchetti, and J.H.M. Schellens The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials Br. J. Cancer 97 2007 577 581
5. A. di Masi et al. Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects Mol. Aspects Med. 30 2009 297 343
6. L.M. Aleksunes, and C.D. Klaassen Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice Drug. Metab. Dispos. 40 2012 1366 1379
7. C. Xu et al. Induction of Phase I, II and III Drug Metabolism/Transport by Xenobiotics Arch. Pharm. Res. 28 2005 249 268
8. N. Albermann et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver Biochem. Pharmacol. 70 2005 949 958
9. S. Harmsen et al. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology Cancer Treat. Rev. 33 2007 369 380
10. D. Wang, and H. Wang Oxazaphosphorine bioactivation and detoxification: the role of xenobiotic receptors Acta Pharm. Sin. B 2 2012 107 117
11. C.S. Chen et al. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450 Drug Metab. Dispos. 33 2005 1261 1267
12. S. Harmsen et al. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors Eur. J. Pharm. Sci. 66 2012 765 771
13. S. Harmsen et al. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor Cancer Chemother. Pharmacol. 64 2009 35 43
14. S.R. Pondugula, and S. Mani Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response Cancer Lett. 328 2013 1 9
15. H. Wang et al. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice J. Clin. Invest. 121 2011 3220 3232
16. D.S. Tan et al. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference Eur. J. Cancer 46 2010 2166 2177
17. J. Kublbeck et al. Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors Eur. J. Pharm. Sci. 40 2010 263 272
18. A.E. Bolton et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects Cancer Chemother. Pharmacol. 53 2004 102 106
19. D.J. Murry et al. Influence of phenytoin on the disposition of irinotecan: a case report J. Pediatr. Hematol. Oncol. 24 2002 130 133
20. D.M. Feng et al. A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity Bioorg. Med. Chem. Lett. 18 2008 682 687
21. K. Zimmermann et al. SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors Bioorg. Med. Chem. Lett. 20 2010 1744 1748
22. S. Mani et al. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents Clin. Cancer Res. 11 2005 6359 6369
23. M. Venkatesh et al. In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation Mol. Pharmacol. 80 2011 124 135
24. H. Wang et al. Activated pregnenolone X-receptor is a target for ketoconazole and its analogs Clin. Cancer Res. 13 2007 2488 2495
25. A. Biswas et al. Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists Pharmaceut. Res. 26 2009 1807 1815
26. S. Mani et al. PXR antagonists and implication in drug metabolism Drug Metab. Rev. 45 2013 60 72
27. C. Zhou et al. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor Mol. Pharmacol. 71 2007 220 229
28. Y. Chen et al. Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor J. Pharmacol. Exp. Ther. 334 2010 999 1008
29. H. Wang et al. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor Mol. Endocrinol. 22 2008 838 857
30. T.W. Synold et al. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux Nat. Med. 7 2001 584 590
31. C. Healan-Greenberg et al. A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor Drug Metab. Dispos. 36 2008 500 507
32. S. Ekins et al. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites Mol. Pharmacol. 72 2007 592 603
33. Y.H. Liu et al. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study Xenobiotica 41 2011 259 280
34. Y. Pan et al. Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening Drug Metab. Dispos. 39 2010 337 344
35. Z. Yiming et al. QSAR prediction of antagonistic activity of PCBs towards human PXR by using heuristic method and best subset modeling Sci. China Chem. 55 2012 1459 1466
36. C.Y. Ung et al. In Silico prediction of pregnane X receptor activators by machine learning approaches Mol. Pharmacol. 71 2006 158 168
37. H. Rao et al. In silico identification of human pregnane X receptor activators from molecular descriptors by machine learning approaches Chemom. Intell. Lab. Syst. 118 2012 271 279
38. C.H. Ngan et al. The structural basis of pregnane X receptor binding promiscuity Biochemistry 48 2009 11572 11581
39. H. van de Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2 2003 192 204
40. N. Greene Computer systems for the prediction of toxicity: an update Adv. Drug Deliv. Rev. 54 2002 417 431
41. S.S. De Buck et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs Drug Metab. Dispos. 35 2007 1766 1780
42. R. Nagaoka et al. Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells Endocrine 30 2006 261 268
43. H. Huang et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole Oncogene 26 2006 258 268
44. B.A. Teicher, and P.A. Andrews Anticancer Drug Development Guide: preclinical screening, clinical trials and approval 2004 Humana Press
45. L.B. Moore et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands J. Biol. Chem. 275 2000 15122 15127
46. S.J. Shukla et al. Identification of pregnane X receptor ligands using time-resolved fluorescence resonance energy transfer and quantitative high-throughput screening Assay Drug Dev. Technol. 7 2009 143 169
47. L. Xiao et al. Evaluation of in vitro PXR-based assays and in silico modeling approaches for understanding the binding of a structurally diverse set of drugs to PXR Biochem. Pharmacol. 81 2011 669 679
48. P. Navaratnarajah et al. Rifampicin-independent interactions between the pregnane X receptor ligand binding domain and peptide fragments of coactivator and corepressor proteins Biochemistry 51 2012 19 31
49. C.B. Mcdonald et al. SH3 domains of Grb2 adaptor bind to PXψPXR Motifs within the Sos1 Nucleotide exchange factor in a discriminate manner Biochemistry 48 2009 4074 4085
50. J. Hu et al. Aroma WaterLOGSY: a fast and sensitive screening tool for drug discovery Magn. Reson. Chem. 48 2010 909 911
51. R.G. Tirona et al. Identification of amino acids in rat pregnane X receptor that determine species-specific activation Mol. Pharmacol. 65 2004 36 44
52. S. De Marino et al. 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity Steroids 77 2012 484 495
53. L.A. Stanley et al. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity Drug Metabol. Rev. 38 2006 515 597
54. M.W. Sinz Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development Drug Metabol. Rev. 45 2013 3 14
55. Z. Zhu et al. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays J. Biomol. Screen. 9 2004 533 540
56. Z. Zhu et al. Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay J. Biomol. Screen. 12 2007 248 254
57. P.B. Desai et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen Drug Metab. Dispos. 30 2002 608 612
58. S. Harmsen et al. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line Cancer Chemother. Pharm. 66 2010 765 771
59. Y. Luo et al. Mammalian two-hybrid system: a complementary approach to the yeast two-hybrid system Biotechniques 22 1997 350 353
60. L. Krausova et al. Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene Biochem. Pharmacol. 82 2011 1771 1780
61. S.A. Jones et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution Mol. Endocrinol. 14 2000 27 39
62. J. Cheng et al. Pregnane X receptor and CYP3A4 humanized mouse models and their applications Br. J. Pharmacol. 163 2011 461 468
63. M. Hasegawa et al. Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver Drug Metab. Dispos. 40 2012 474 480
64. S.C. Nallani et al. Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor Drug Metab. Dispos. 31 2003 681 684
65. E. Schuetz et al. Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents Mol. Pharmacol. 62 2002 439 445
66. S. Ekins et al. Evolution of pharmacologic specificity in the pregnane X receptor BMC Evol. Biol. 8 2008 103 124
67. L.B. Moore et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors Mol. Endocrinol. 16 2002 977 986
68. T. Bresolin et al. Expression of PXR, CYP3A and MDR1 genes in liver of zebrafish Comp. Biochem. Phys. C 140 2005 403 407
69. C. Parng et al. Zebrafish: a preclinical model for drug screening Assay Drug Dev. Technol. 1 2002 41 48
70. N.S. Sipes et al. Zebrafish As an integrative model for twenty first century toxicity testing Birth Defects Res., Part C: Embryo Today: Rev. 93 2011 256 267
71. J.C. Stevens et al. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities Drug Metab. Dispos. 21 1993 753 760
72. S. Kim et al. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction Drug Metab. Dispos. 38 2010 16 24